Theravance Biopharma announced a major restructuring after its phase III ampreloxetine program missed its primary endpoint, triggering a decision to wind down the company’s entire R&D organization and cut approximately 50% of its workforce. The company will focus on commercial execution of its approved respiratory product (Yupelri) and pursue options including a potential sale. Ampreloxetine, a norepinephrine reuptake inhibitor, had previously failed a late‑stage test, and the most recent negative readout convinced board and management the asset no longer supported a standalone R&D engine. Theravance expects these moves to reduce cash burn by roughly 60% and to generate annualized cash flow from existing commercial interests. The decision illustrates the asymmetric risk of single‑asset biotechs and highlights how late‑stage clinical failures can force rapid strategic pivots—affecting patients, trial participants, vendors, and capital markets. For competitors, the move may reallocate clinical talent and assets into the respiratory and bronchodilator markets.